Provided is a method of encapsulation, the method including: providing a first mixture; applying heat to the first mixture until the first mixture reaches a first temperature; providing a second mixture; applying heat to the second mixture until the second mixture reaches a second temperature; mixing the first mixture with the second mixture to obtain a third mixture; providing a fourth mixture; applying heat to the fourth mixture until the fourth mixture reaches a third temperature; mixing the third mixture with the fourth mixture to obtain a fifth mixture.

A live bacteria-containing particulate is provided, wherein the particulate comprises a bacterial strain, a first covering layer, and a second covering layer, and wherein the first covering layer is in-between the cell membrane and cell wall of the bacterial strain and the bacterial strain is dispersed in the second covering layer. A method of preparing a live bacteria-containing particulates is also provided, wherein the method comprises the following steps: (a) subjecting a bacterial strain to a three-stage fermentation to obtain a fermentation broth; (b) concentrating the fermentation broth to provide a concentrated bacterial solution; (c) mixing the concentrated bacterial solution with a protective agent; and (d) drying the mixture to provide live bacteria-containing particulates.

Provided herein are chewable oral formulations including pimobendan for use in mammals to treat cardiac disorders.

Compositions and methods are disclosed for treating anxiety or stress in an animal, for reducing elevated levels of 4-EPS in an animal with elevated 4-EPS levels, for preventing elevated levels of 4-EPS in an animal and for promoting growth of beneficial microbes in an animal's microbiome and inhibiting growth of non-beneficial microbes. The methods comprise administering to the animal an effective amount of soy protein and vitamin C. Compositions are disclosed which comprise amounts of soy protein and vitamin C effective for use in the methods.

An aqueous liquid suspension containing a coated drug—ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine—ion exchange resin complex is provided. The coated amphetamine—ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.

Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.

The present invention relates to improved formulations of propandiol mononitrate and derivatives thereof as well as to the production of such formulations.

An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and optionally a lubricant derived from rice hulls (e.g., a multi-component integral lubricant).

A single dose vaporizable formulation including room temperature solid extracts and other botanical extracts and methods of processing and packaging single dose portions of vaporizable formulations. Also, methods of dispensing single dose portions, including segmented dose formulations and applicator-tab devices for vaporizers. A vaporizer having a heating chamber element with an indentation or cavity sized to receive a similarly-shaped, single dose vaporizable formulation.

The present invention relates to polymorphic forms of dasatinib lauryl sulfate salt.